Project Grant HT94252510054
Award Date
4/1/25
Completion Date
3/31/27
Dollars Obligated
$294K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Israel
Similar Awards
The Defense Health Agency awarded The Trustees of Columbia University in the City of New York, doing business as Health Sciences Division, a $1,986,275 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant supports the development of biofabricated, patient-specific skin gloves as a personalized therapy for mitten deformities in epidermolysis bullosa, a rare genetic skin disorder. The project will run from June 15, 2023 to June 14, 2027. The...
The Defense Health Agency awarded a $4.66 million project grant to the University of Colorado Denver to support research on a stem cell-based therapy for recessive dystrophic epidermolysis bullosa delivered with a spray-on skin device. The grant was awarded on September 1, 2023 under the Military Medical Research and Development program (CFDA 12.420) and will run through August 31, 2027. Through this funding, the University of Colorado Denver will conduct research to develop an innovative...
The Defense Health Agency awarded a $4,288,290 Project Grant to Eliksa Therapeutics, Inc. of Doylestown, PA under the Military Medical Research and Development program (CFDA 12.420). The grant supports the development of a novel ophthalmic solution to treat the ocular manifestations of epidermolysis bullosa, a rare and debilitating genetic skin disorder. The funding will enable Eliksa Therapeutics to conduct research and clinical trials over a 2-year period from July 1, 2024 to June 30, 2026,...
The Department of the Army Medical Command awarded a $409,121 project grant to the Rochester Institute of Technology under the Military Medical Research and Development program (CFDA 12.420). The grant will fund the development of a novel 3D scleroderma skin model to test therapeutic modulation of TRPC6 from July 2022 through July 2025. Through this research, the awardee aims to advance the development of medical solutions for the battlefield by investigating potential treatments for...
The U.S. Defense Health Agency awarded a $388,060 Project Grant to the Hebrew University of Jerusalem's Authority for Research and Development Division under the Department of Defense's Military Medical Research and Development program (CFDA 12.420). The 2-year grant, which runs from September 30, 2023 to September 29, 2025, will fund epigenetic liquid biopsy research for Duchenne and Becker muscular dystrophy. The Hebrew University, a leading academic institution in Israel, will conduct the...
This Project Grant award of $1,558,753.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the University of Cincinnati in conducting tissue engineering research for cutaneous and systemic epidermolysis bullosa gene therapy. The award period runs from September 1, 2023 to August 31, 2026.
The University of Cincinnati, through its Sponsored Research Services Division, is the prime awardee on this grant. As a subcontractor, the...
The Ohio State University was awarded a $971,401 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct tissue engineering research for cutaneous and systemic epidermolysis bullosa gene therapy. The project will run from September 1, 2023 to August 31, 2026. Epidermolysis bullosa is a rare genetic condition that causes fragile, blistering skin. This research aims to develop innovative gene therapy treatments to address...
The Department of the Army Medical Command awarded New York University School of Medicine a $1,186,500 project grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 2021 through August 2024 to understand the transition from nevi to melanoma occurring within the skin epidermis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...
This Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) provides $725,001.00 to Thomas Jefferson University - Sidney Kimmel Medical College to conduct research aimed at "Improving Wound Healing and Recovery by Blocking Excessive Scar Formation in Peripheral Nerves, Muscles, and Joints After Composite Injuries to Extremities." The research, which will take place in Philadelphia, PA, is intended to transform healthcare for...
The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and...